At least that is according to a Phase 2 study by Elan and Wyeth.
Patients treated with bapineuzumab recorded a 2.3-point improvement over placebo on the ADAS-cog test, a measure of cognitive function. The result was not statistically significant. Likewise, bapineuzumab patients did not perform better on a functional endpoint, the Disability Assessment Scale for Dimentia.
The good news is if you don't have a a gene called ApoE4 then this drug might actually help you a little bit. A 5 point improvement on this test doesn't seem like a big improvement to me but I guess it is better then nothing.
In these non-carrier patients, treatment with bapineuzumab compared to placebo resulted in a statistically significant, five-point benefit in the ADAS-cog score. Other measures of cognition and function were also statistically significantly improved in favor of bapineuzumab.
No comments:
Post a Comment